What the changes say
- AI deployment is newly identified as a business, operational, cost, competitiveness, and reputation risk.
- U.S. healthcare regulation is described as increasingly uncertain, potentially creating new or modified requirements.
- International sales remained a majority of revenue in fiscal 2025, while net intangible assets declined to $9.0 billion.
- The quarterly dividend stayed at $0.07 per share, but the Board retains discretion to reduce or eliminate it.
What changed since the prior 10-K
New
- NewRisks Related to our Business Operations and Industry
Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation
AI may introduce flawed or biased outputs, employee errors, higher costs, deployment delays, and competitive disadvantages across products and internal operations.
Reworded
- 44% rewrittenRisks Related to Ownership of our Common Stock
Dividends on our common stock could be reduced or eliminated in the future
Dividend disclosures moved to fiscal 2025 and 2026; the quarterly amount remains $0.07, with the same reduction or elimination risk.
- 36% rewrittenRisks Related to Legal, Government and Regulatory Matters
The healthcare industry is highly regulated and if we fail to comply with its extensive system of laws and regulations, we could suffer fines and penalties or be required to make significant changes to our operations which could have a significant adverse effect on the results of our business operations
The risk now emphasizes U.S. healthcare regulatory uncertainty and potential new or modified regulations, replacing language about strengthening federal oversight.
- 31% rewrittenRisks Related to our Foreign Operations
Economic, political and other risks associated with foreign operations could adversely affect our international sales and profitability
The majority-of-revenue statement now refers to fiscal 2025 instead of fiscal 2024; international manufacturing, employees, and suppliers remain highlighted.
- 27% rewrittenRisks Related to our Business Operations and Industry
Our results of operations will be adversely affected if we fail to realize the full value of our intangible assets
Net intangible assets decreased from $9.1 billion at December 29, 2024 to $9.0 billion at December 28, 2025; impairment procedures remain unchanged.
All 21 risk factors
Headings as the filing states them, in filing order.
Risks Related to our Business Operations and Industry
- 01Our growth and profitability are subject to global economic and political conditions, and operational disruptions at our facilities
- 02If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets
- 03We may not be able to successfully execute acquisitions or divestitures, license technologies, integrate acquired businesses or licensed technologies into our existing businesses, maintain licensed technologies, or make acquired businesses or licensed technologies profitable
- 04If we do not compete effectively, our business will be harmed
- 05Our quarterly operating results could be subject to significant fluctuation, and we may not be able to adjust our operations to effectively address changes we do not anticipate, which could increase the volatility of our stock price and potentially cause losses to our shareholders
- 06A significant disruption in third-party package delivery and import/export services, or significant increases in prices for those services, could interfere with our ability to ship products, increase our costs and lower our profitability
- 07Disruptions in the supply of raw materials, certain key components and other goods from our limited or single source suppliers could have an adverse effect on the results of our business operations, and could damage our relationships with customers
- 08If we do not retain our key personnel, our ability to execute our business strategy will be limited
- 09Our success also depends on our ability to execute leadership succession plans. The inability to successfully transition key management roles could have a material adverse effect on our operating results
- 10Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputationNew
- 11Our results of operations will be adversely affected if we fail to realize the full value of our intangible assets27% rewritten
Risks Related to our Intellectual Property
- 12We may not be successful in adequately protecting our intellectual property
- 13If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage
Risks Related to Legal, Government and Regulatory Matters
- 14The manufacture and sale of products and services may expose us to product and other liability claims for which we could have substantial liability
- 15Changes in governmental regulations may reduce demand for our products or increase our expenses
- 16The healthcare industry is highly regulated and if we fail to comply with its extensive system of laws and regulations, we could suffer fines and penalties or be required to make significant changes to our operations which could have a significant adverse effect on the results of our business operations36% rewritten
Risks Related to our Foreign Operations
- 17Economic, political and other risks associated with foreign operations could adversely affect our international sales and profitability31% rewritten
Risks Related to our Debt
- 18We have a substantial amount of outstanding debt, which could impact our ability to obtain future financing and limit our ability to make other expenditures in the conduct of our business
- 19Restrictions in our senior unsecured revolving credit facility and other debt instruments may limit our activities
Risks Related to Ownership of our Common Stock
- 20Our share price will fluctuate
- 21Dividends on our common stock could be reduced or eliminated in the future44% rewritten
Other Revvity 10-Ks
- FY2024 10-K risk factors20 risks
Revvity relies heavily on international sales, which generated a majority of its 2024 revenue.
Filed Feb 25, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.